Application of Akkermansia muciniphila in preparing medicine for preventing and treating enteritis

By isolating and applying AKK ONE, the problems in the prior art are difficult to effectively alleviate the symptoms and potential mechanisms of ulcerative colitis, and the effect of relieving colon inflammation by changing the composition of intestinal flora and increasing the production of short-chain fatty acids is achieved.

CN118286268BActive Publication Date: 2025-03-28THANKCOME BIOLOGICAL SCI & TECH CO LTD
0 Cites 1 Cited by

Patent Information

Application Number
CN202410442188.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-12
Publication Date
2025-03-28
Estimated Expiration
2044-04-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively alleviate the symptoms and potential mechanisms of ulcerative colitis (UC), and the role of traditional probiotics in improving diseases is not significant.

Method used

Akkermansia muciniphila, named AKK ONE, was used to prepare drugs to prevent enteritis by increasing the production of short-chain fatty acids, promoting the differentiation of regulatory T cells and changing the composition of intestinal flora.

Benefits of technology

AKK ONE significantly improved physiological abnormalities, pathological damage and immunomodulation in the DSS-induced mouse colitis model, and had clinical application prospects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a novel Akkermansia muciniphila for preparing a drug for preventing and treating enteritis, and its use in preparing a drug for preventing and treating enteritis belongs to the field of microbial technology. The Akkermansia muciniphila is AKK ONE, and its deposit number is: CGMCC No.20954. The AKK ONE strain of the present invention has certain safety, can improve related pathological damage and immune regulation in an enteritis mouse model, and has a positive regulatory effect on the intestinal microbial community and short-chain fatty acid level of experimental animals, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art